The FDA cited in its letter to SK several issues with the risk and benefit information presented about Xcopri in the ad. For ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

Anti-vaccine sentiment is alive and well, especially in the U.S. And it was evident in recent weeks as drugmakers revealed ...

Eli Lilly is continuing its recent pattern of tying disease awareness-raising efforts to major pop cultural moments. | Eli Lilly's latest high-profile crossovers—which include a starry TV partnership ...

Maryland is becoming the home away from home for British drugmaker AstraZeneca. | Maryland is becoming the home away from ...

As the researchers behind Pfizer and Astellas' Padcev and Merck's Keytruda have taken victory laps on the heels of the ...

The FDA has opened an investigation into Takeda’s recombinant protein med Adzynma following the reported death of a pediatric patient who received the drug. | The FDA has opened an investigation into ...

After months of legal attempts to get out of its $430 million buyout of Australia’s Mayne Pharma, Cosette Pharmaceuticals has received a lifeline from the Australian government. | Cosette had been ...

Texas Attorney General Ken Paxton filed a lawsuit Thursday on behalf of the state that takes aim at “false, misleading, and ...

Some four years into Jemperli’s commercial lifespan, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. | Some four years into ...

A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to ...